Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Siamab Therapeutics

Request full access

Therapies targeting abnormal carbohydrates found only on cancer cells

Newton, United StatesFounded 2006Biotech & Life Sciences

About Siamab Therapeutics

Siamab Therapeutics, Inc. was a biopharmaceutical firm that operated in the oncology space, focusing on the development of therapeutics for difficult-to-treat solid tumors. Founded in 2006 by Dr. Ajit Varki, a distinguished professor at the University of California, San Diego (UCSD), the company was built upon his foundational research in glycobiology. The company's scientific focus originated from Dr. Varki's discoveries related to the unique sugars, specifically tumor-associated carbohydrate antigens (TACAs), found on the surface of cancer cells. In 2015, the company relocated to Massachusetts, adopting a capital-efficient, semi-virtual operational model. Jeff Behrens, an entrepreneur with a diverse background in healthcare IT and biotechnology, including roles at Biogen Idec and Edimer Pharmaceuticals, served as the President and CEO.

The core of Siamab's business was its proprietary technology platform designed for the rapid discovery and development of therapeutic antibodies that target TACAs. These antigens are compelling targets because they are highly specific to cancer cells and are associated with chemoresistance and the suppression of immune function in solid tumors. The company's business model revolved around advancing its proprietary antibody candidates through preclinical development and forging strategic collaborations with larger pharmaceutical companies. This strategy was validated through a significant collaboration with Boehringer Ingelheim to discover antibody therapeutics against TACAs. The company operated on a lean model, successfully raising over $12 million from angel investors and leveraging an additional $7 million from grants and corporate partnerships, a notable achievement without traditional venture capital funding.

Siamab's lead program, ST1, was an antibody-drug conjugate (ADC) targeting Sialyl-Tn (STn), a specific TACA expressed in a variety of solid tumors, including ovarian, pancreatic, colon, and prostate cancers. The presence of STn is linked to metastatic disease, poor prognosis, and reduced survival. The ST1 therapeutic was engineered to bind with high specificity and affinity to STn, enabling the targeted delivery of a cytotoxic agent to cancer cells. Preclinical studies demonstrated ST1's efficacy in inhibiting tumor growth in multiple cancer models, with complete regression observed in some cases, alongside a favorable safety profile in non-human primate studies. A significant finding was ST1's ability to also target and deplete myeloid-derived suppressor cells (MDSCs), which inhibit the body's immune response against tumors, suggesting a dual-action mechanism. In August 2019, Siamab was acquired by an undisclosed large biopharmaceutical company in a deal valued at up to $202 million, marking a successful exit for its angel investors and validating its focused approach to oncology research.

Source: Dealroom company data

Siamab Therapeutics in the Newton ecosystem

Live from Dealroom

The Siamab Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed2 investors entered at this stage

  • Mass Medical Angels
  • Boston Harbor Angels

Series A1 investor entered at this stage

  • Bantam Group
Team profiled 7 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Newton HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Siamab Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Siamab Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.